HRP20160308T1 - Nova protutijela - Google Patents

Nova protutijela Download PDF

Info

Publication number
HRP20160308T1
HRP20160308T1 HRP20160308TT HRP20160308T HRP20160308T1 HR P20160308 T1 HRP20160308 T1 HR P20160308T1 HR P20160308T T HRP20160308T T HR P20160308TT HR P20160308 T HRP20160308 T HR P20160308T HR P20160308 T1 HRP20160308 T1 HR P20160308T1
Authority
HR
Croatia
Prior art keywords
antibody
vegf
sequence
disease
integrin
Prior art date
Application number
HRP20160308TT
Other languages
English (en)
Inventor
Wei-Ching Liang
Gregory D. Plowman
Yan Wu
Weilan Ye
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HRP20160308T1 publication Critical patent/HRP20160308T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

1. Humanizirano integrinsko protutijelo anti-α5β1, naznačeno time, da obuhvaća sekvencu varijabilne domene slabog lanca koja obuhvaća sljedeće: (1) LHVR1 koja sadrži aminokiselinsku sekvencu KASQSVGSDVA, (2) LHVR2 koja sadrži aminokiselinsku sekvencu STSYRYS i (3) LHVR3 koja sadrži aminokiselinsku sekvencu QQYSSYPFT, te obuhvaća sekvencu varijabilne domene jakog lanca koja obuhvaća sljedeće: (1) HHVR1 koja sadrži aminokiselinsku sekvencu GYTFTDYYLY ili GYTFSDYYLY, (2) HHVR2 koja sadrži aminokiselinsku sekvencu GISPSSGGTTFADAFEG i (3) HHVR3 koja sadrži aminokiselinsku sekvencu DAYGDWYFDV.
2. Integrinsko protutijelo anti-α5β1, naznačeno time, da obuhvaća varijabilnu domenu slabog lanca koja ima sekvencu iznesenu u SEQ ID NO:2, i varijabilnu domenu jakog lanca koja ima sekvencu iznesenu u SEQ ID NO:6.
3. Protutijelo prema zahtjevu 1, naznačeno time, da varijabilna domena slabog lanca ima sekvencu iznesenu u SEQ ID NO:3, i varijabilna domena jakog lanca ima sekvencu iznesenu u SEQ ID NO:8.
4. Protutijelo prema zahtjevu 1, 2 ili 3, naznačeno time, da to protutijelo ne veže integrin alfaVbeta3 niti integrin alfaVbeta5 niti integrin alfaVbeta1.
5. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time, da to protutijelo obuhvaća Fc-sekvencu od humanog IgG, pri čemu je humani IgG opcijski hlgG1 ili hlgG4.
6. Protutijelo prema zahtjevu 5, naznačeno time, da to protutijelo obuhvaća Fc-sekvencu kojoj nedostaje funkcija djelovatelja staničnog citotoksiciteta ovisnog o protutijelu (ADCC), pri čemu Fc-sekvenca opcijski sadrži supstituciju D265A.
7. Protutijelo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da je to protutijelo odabrano iz skupine koju čine: Fab, Fab', F(ab)'2, Fv(scFv) jednostrukog lanca, Fv-fragment; bivalentni i bispecifični fragment protutijela i linearno protutijelo.
8. Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da to protutijelo je multispecifično protutijelo.
9. Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da je to protutijelo konjugirano na terapeutsko sredstvo, pri čemu je terapeutsko sredstvo opcijski odabrano iz skupine koju čine: citotoksičko sredstvo, radioizotop i kemoterapeutsko sredstvo.
10. Protutijelo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da je to protutijelo konjugirano na oznaku, pri čemu je ta oznaka opcijski odabrana iz skupine koju čine: radioizotop, fluorescentna boja i enzim.
11. Sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljiv nosač.
12. Integrinsko protutijelo anti-α5β1 prema bilo kojem od zahtjeva 1 do 9, naznačeno time, da se upotrebljava u postupku liječenja bolesti ili poremećaja kod pojedinca, pri čemu bolest ili poremećaj ima abnormalnu angiogenezu, gdje se integrinsko protutijelo anti-α5β1 primjenjuje u kombinaciji s VEGF-antagonistom ili gdje se pojedinac liječi s VEGF-antagonistom i uzastopno se primjenjuje integrinsko protutijelo anti-α5β1, pri čemu je bolest opcijski rak, očna bolest ili autoimuna bolest, dok je VEGF-antagonist odabran iz skupine koju čine: protutijelo, imunoadhezin, peptitijelo i nukleinska kiselina koja se hibridizira u molekulu nukleinske kiseline koja kodira VEGF pod strogo definiranim uvjetima.
13. Integrinsko protutijelo anti-α5β1 za uporabu prema zahtjevu 12, naznačeno time, da se VEGF-antagonist može konkurentno sprečavati od spajanja na humani VEGF pomoću bavacizumaba, pri čemu je VEGF-antagonist opcijski bevacizumab.
14. Sastav, naznačen time, da obuhvaća VEGF-antagonist, protutijelo prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prihvatljiv nosač, pri čemu je VEGF-antagonist odabran iz skupine koju čine: protutijelo, imunoadhezin, peptitijelo i nukleinska kiselina koja se hibridizira u molekulu nukleinske kiseline koja kodira VEGF pod strogo definiranim uvjetima.
15. Sastav prema zahtjevu 14, naznačen time, da se upotrebljava u postupku liječenja bolesti ili poremećaja kod pojedinca, pri čemu bolest ili poremećaj ima abnormalnu angiogenezu, dok je bolest opcijski rak, očna bolest ili autoimuna bolest.
HRP20160308TT 2007-09-26 2016-03-23 Nova protutijela HRP20160308T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97547107P 2007-09-26 2007-09-26
EP08834260.5A EP2200700B1 (en) 2007-09-26 2008-09-25 Novel antibodies
PCT/US2008/077622 WO2009042746A1 (en) 2007-09-26 2008-09-25 Novel antibodies

Publications (1)

Publication Number Publication Date
HRP20160308T1 true HRP20160308T1 (hr) 2016-04-22

Family

ID=40329277

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160308TT HRP20160308T1 (hr) 2007-09-26 2016-03-23 Nova protutijela

Country Status (22)

Country Link
US (3) US7973138B2 (hr)
EP (1) EP2200700B1 (hr)
JP (1) JP2011501656A (hr)
KR (1) KR20100065162A (hr)
CN (1) CN101888878B (hr)
AR (1) AR066170A1 (hr)
AU (1) AU2008304452B2 (hr)
BR (1) BRPI0816049A2 (hr)
CA (1) CA2698609A1 (hr)
CL (1) CL2008002856A1 (hr)
CO (1) CO6260094A2 (hr)
DK (1) DK2200700T3 (hr)
HR (1) HRP20160308T1 (hr)
HU (1) HUE027911T2 (hr)
MX (1) MX2010003325A (hr)
MY (1) MY151191A (hr)
NZ (1) NZ584838A (hr)
PE (1) PE20091029A1 (hr)
RU (1) RU2490277C2 (hr)
SI (1) SI2200700T1 (hr)
TW (1) TWI547503B (hr)
WO (1) WO2009042746A1 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
CA2753988C (en) * 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
JP5383905B2 (ja) 2009-05-08 2014-01-08 ジェネンテック， インコーポレイテッド ヒト化抗ｅｇｆｌ７抗体とその使用方法
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
EP3553089A1 (en) 2012-05-10 2019-10-16 Bioatla, LLC Multi-specific monoclonal antibodies
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
CN104994874B (zh) 2012-12-26 2017-04-12 安科协同公司 抗整联蛋白β1抗体组合物及其使用方法
EP2948472B1 (en) 2013-01-23 2019-05-22 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2014122144A1 (en) * 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
JP6445467B2 (ja) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN108693004B (zh) * 2018-05-24 2020-08-04 中国农业科学院农业质量标准与检测技术研究所 一种检测菜籽粕中是否掺杂抗生素滤渣的方法
KR20220047536A (ko) * 2019-04-01 2022-04-18 레이크파르마, 인코퍼레이티드 면역반응의 조절 및 질병의 치료를 위한 btla-결합(cd272) 항체
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN114688461A (zh) * 2020-12-31 2022-07-01 青岛海尔施特劳斯水设备有限公司 一种漏水检测方法及系统
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN114073996B (zh) * 2021-11-24 2023-04-14 中山大学 一种嵌套式微井阵列芯片及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
PT719859E (pt) 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
ID27810A (id) 1998-01-23 2001-04-26 Merck Patent Gmbh Antibodi menoclonal anti v-integrin dan kegunaan untuk mencegah penambahan v 6-integrin untuk fibronectin
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
PT1075277E (pt) 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20040009494A1 (en) 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20020019330A1 (en) 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20020015970A1 (en) 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2001011086A2 (en) 1999-08-11 2001-02-15 Eos Biotechnology, Inc. Methods of screening for angiogenesis modulators
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
EP1418943A1 (en) 2001-02-14 2004-05-19 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2451465A1 (en) 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004001384A2 (en) 2002-06-25 2003-12-31 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
EP1539247A4 (en) 2002-07-16 2007-08-29 Univ New Jersey Med ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
ES2387985T3 (es) * 2002-11-26 2012-10-05 Abbott Biotherapeutics Corp. Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
NZ549893A (en) * 2004-03-24 2010-05-28 Facet Biotech Corp Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
US20090137601A1 (en) 2005-11-23 2009-05-28 Astrazeneca Ab L-Phenylalanine Derivatives
US20090111828A1 (en) 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
US20090203663A1 (en) 2006-02-09 2009-08-13 Astrazeneca Ab Chemical compounds
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
EP2032605A2 (en) 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
KR20100115360A (ko) 2008-02-05 2010-10-27 브리스톨-마이어스 스큅 컴퍼니 알파 ５-베타 １ 항체 및 이의 용도

Also Published As

Publication number Publication date
EP2200700A1 (en) 2010-06-30
AU2008304452A1 (en) 2009-04-02
MX2010003325A (es) 2010-04-09
AU2008304452B2 (en) 2014-01-16
CO6260094A2 (es) 2011-03-22
BRPI0816049A2 (pt) 2019-09-24
SI2200700T1 (sl) 2016-04-29
AR066170A1 (es) 2009-07-29
US8840887B2 (en) 2014-09-23
RU2010116184A (ru) 2011-11-10
CL2008002856A1 (es) 2009-01-16
TWI547503B (zh) 2016-09-01
US20090098112A1 (en) 2009-04-16
WO2009042746A1 (en) 2009-04-02
RU2490277C2 (ru) 2013-08-20
NZ584838A (en) 2012-08-31
JP2011501656A (ja) 2011-01-13
TW200924794A (en) 2009-06-16
MY151191A (en) 2014-04-30
CA2698609A1 (en) 2009-04-02
CN101888878A (zh) 2010-11-17
PE20091029A1 (es) 2009-08-19
HUE027911T2 (en) 2016-11-28
US7973138B2 (en) 2011-07-05
US9284376B2 (en) 2016-03-15
CN101888878B (zh) 2014-05-21
EP2200700B1 (en) 2016-01-13
US20120156129A1 (en) 2012-06-21
KR20100065162A (ko) 2010-06-15
US20120148572A1 (en) 2012-06-14
DK2200700T3 (en) 2016-04-11

Similar Documents

Publication Publication Date Title
HRP20160308T1 (hr) Nova protutijela
RU2020120539A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
HRP20160082T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2011501656A5 (hr)
SI2842573T1 (en) Monoclonal antibodies against the receptor 2 of the fibroblast growth factor
JP2010501164A5 (hr)
JP2010513303A5 (hr)
JP2018512145A5 (hr)
JP2017529838A5 (hr)
JP2009529920A5 (hr)
JP2005515963A5 (hr)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2011509245A5 (hr)
HRP20130922T1 (hr) U potpunosti humana protutijela protiv humanog 4-1bb (cd137)
RU2013123927A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173
JP2008543339A5 (hr)
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
EP3626747A1 (en) Novel recombinant bifunctional fusion protein, preparation method therefor and use thereof
RU2007140311A (ru) Антитела и родственные молекулы, связываюшиеся с белками 161p2f10b
JP2005505256A5 (hr)
RU2012113554A (ru) Антитела к рецепту глюкагана и их использование
JP2010509931A5 (hr)